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Introduction {#sec1}
============

Induced pluripotent stem cell (iPSC) technology holds unparalleled promise for research, tissue engineering, and regenerative medicine. Reprogramming is a continuous process characterized by the stepwise activation of fundamental pluripotency genes ([@bib4], [@bib39]) and the silencing of somatic cell-of-origin genes ([@bib5]). This complex remodeling of transcriptional networks is associated with reprogramming of the epigenome ([@bib4], [@bib37], [@bib39]), which is the ensemble of DNA or chromatin modifications linked with gene expression states without affecting DNA sequence. Specific histone marks are lost ([@bib8], [@bib13], [@bib49]) or acquired ([@bib5], [@bib6], [@bib24]) during reprogramming, and activation of microRNAs ([@bib29]) and long noncoding RNAs ([@bib18]) at defined stages is also important. A critical role for DNA demethylation in complete and robust reprogramming of terminally differentiated cells has been proposed ([@bib27]); however, the molecular mechanisms underlying this epigenetic process and its dynamics at different stages during reprogramming are poorly understood. It is also not clear to what extent demethylation is involved in the creation of a pluripotent cell identity and whether it may also be needed to remove epigenetic memory.

iPSCs have been shown to tolerate global hypomethylation, just as embryonic stem cells (ESCs) do ([@bib47]), and the efficiency of obtaining these cells is improved by treatment with 5-azacytidine ([@bib24]). Tet family dioxygenases hydroxylate 5-methylcytosine (5mC) and enhance reprogramming efficiency ([@bib9], [@bib11], [@bib17]). The cytosine deaminase activation-induced cytidine deaminase (AID) stabilizes the pluripotent phenotype ([@bib19]) and is needed for demethylation of specific promoters in heterokaryon reprogramming ([@bib1]), but the extent, timing, and mechanisms of this demethylation in iPSC reprogramming are not known.

Despite demethylation being critical, there are only a few comprehensive studies of DNA methylation dynamics during the reprogramming process and none in a primary reprogramming system. [@bib29], using a methylation array to study promoter regions, showed that demethylation occurs gradually, while new methylation marks are gained only late in reprogramming. More recently, [@bib20] performed genome-wide analyses in intermediates of F-class cells (an alternative pluripotent state, dependent on continuous high expression levels of the Yamanaka Factors \[Oct3/4, Sox2, Klf4, cMyc\] OSKM) and one late time point where OSKM were no longer exogenously expressed. They demonstrated that hypomethylated differentially methylated regions (DMRs) are highly enriched in H3K4me3 and H3K27me3 and that the majority of these overlap with specific transcription factor binding sites. However, it is not clear how DNA methylation marks at regulatory regions are remodeled during primary iPSC reprogramming and how this is linked to the establishment of the pluripotent gene expression program. Here, we perform a comprehensive genome-wide in-depth analysis of the dynamics of DNA demethylation and its link to transcription during primary mouse embryonic fibroblast (MEF) reprogramming to iPSCs. We demonstrate that both female and male cells undergo global hypomethylation of the genome, which is likely to be important for the removal of epigenetic memory. Independently, targeted loss of DNA methylation marks at critical regulatory regions is necessary for the establishment of cell identity. We show that global demethylation is more pronounced in female cells, while targeted demethylation at regulatory regions is evident in both female and male cells. Finally, we find that AID plays a key role in global demethylation and epigenetic memory erasure. Surprisingly, this occurs at the level of regulation of UHRF1 protein, an essential component of the DNA methylation maintenance machinery, recently also shown to be regulated during global demethylation in ESCs transitioning from serum to 2i ([@bib46]).

Results {#sec2}
=======

iPSC Reprogramming Triggers Transient Global DNA Hypomethylation {#sec2.1}
----------------------------------------------------------------

To enable dynamic methylation profiling, reprogramming intermediates were analyzed at defined time points ([Figure 1](#fig1){ref-type="fig"}A; for a detailed description, see [Experimental Procedures](#sec4){ref-type="sec"}). Oct4-GFP MEFs were reprogrammed in low oxygen (5% O~2~), known to improve reprogramming ([@bib50]), in serum medium and using an inducible piggybac system. This allowed us to obtain and pick colonies as early as day 6 (d6) after induction of OSKM by doxycycline (Dox) and analyzing these same clones over time, allowing for the characterization of intermediate time points that are not accessible through primary reprogramming carried out in normoxic conditions ([Figure 1](#fig1){ref-type="fig"}A). Female and male iPSC clones at intermediate-late stages of reprogramming (d21 and d29 iPSCs) already express the majority of the pluripotency factors, but in contrast to established iPSCs (d60 iPSCs) female cells are still in the process of downregulating Xist and thus in the process of completing X chromosome reactivation ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Dox-independent GFP-positive colonies at d21 that showed expression of key pluripotency markers and the ability to differentiate into the three germ layers as well as a normal karyotype by d60 ([Figures S1](#mmc1){ref-type="supplementary-material"}B--S1D) were used in subsequent analyses. Embryonic stem cells (ESCs) were included in the analysis as a control for pluripotent cells.

Notably, liquid chromatography mass spectrometry (LC-MS) revealed substantial global demethylation in intermediate-late stages of reprogramming in female cells ([Figure 1](#fig1){ref-type="fig"}B). While methylation levels comparable to MEFs (3.0%) were maintained at d6 (d6T^+^/S^--^: 3.0% and d6T^--^/S^+^: 3.1%), in intermediate-late stages there was a significant decrease in 5-methylcytosine (5mC) levels (d21 iPSCs: 2.7% and d29 iPSC: 2.4%, p \< 0.05: MEFs versus d29 iPSCs, ANOVA with Dunnett's correction). However, this global hypomethylation was transient with established iPSCs's 5mC levels (3.8%) similar to those of primed ESCs (3.9%). Global demethylation during reprogramming of female cells was confirmed by whole-genome bisulphite sequencing (WGBS), which revealed a substantial drop in CpG methylation levels from 68% in MEFs to 45% in d29 iPSCs, with subsequent remethylation to 67% in d60 iPSCs ([Figures 1](#fig1){ref-type="fig"}C, [S1](#mmc1){ref-type="supplementary-material"}E, and S1G). Interestingly, during reprogramming of male cells this global demethylation was not as marked as in female cells ([Figures 1](#fig1){ref-type="fig"}D, [S1](#mmc1){ref-type="supplementary-material"}F, and S1G).

The methylation dynamics during iPSC reprogramming closely resembled the transient loss of DNA methylation marks in early embryo development, where DNA methylation is globally lost from the oocyte (52%) to the 2- and 4-cell stage (47% and 38%) until it reaches very low levels (20%) in the inner cell mass (ICM) at the blastocyst stage. Methylation marks are then regained by the E6.5 epiblast stage (61%) ([Figures 1](#fig1){ref-type="fig"}E and [S1](#mmc1){ref-type="supplementary-material"}H). Moreover, global demethylation was uncoupled from transcriptional regulation ([Figure S1](#mmc1){ref-type="supplementary-material"}I) as previously reported in primordial germ cell (PGCs) development, and in the transition from primed to naive ESCs ([@bib32], [@bib12]).

These results show that global DNA demethylation occurs in the intermediate-late stages of reprogramming and that female and male cells undergo different modulation of DNA methylation dynamics during reprogramming.

Stable Targeted DNA Demethylation Occurs at Pluripotency Regulatory Regions and Correlates with Expression of the Pluripotency Network {#sec2.2}
--------------------------------------------------------------------------------------------------------------------------------------

In order to integrate and validate the differences in global methylation levels observed between the discrete time points within our experiment, the development of specific analytical approaches was required. These approaches also allowed insights into other reprogramming systems, thus highlighting their usefulness (for detailed description, see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}). The first approach employs a background model to correct for global methylation differences, which allowed us to confidently call differentially methylated regions (DMRs) from MEFs to established iPSCs. Gene bodies, intergenic regions, and long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs) have a similar methylation profile to the genome as a whole and hence follow the global demethylation and remethylation event ([Figures 2](#fig2){ref-type="fig"}A and [S2](#mmc1){ref-type="supplementary-material"}A). In contrast, intracisternal A particle (IAP) retrotransposons and limb enhancers (as an example of a tissue-specific enhancer) are protected from demethylation, with many DMRs being hypermethylated in the established iPSCs. Notably, pluripotency regulatory regions such as promoters, ESC enhancers, and super-enhancers (SEs) are specifically targeted for demethylation, with the majority of these DMRs being hypomethylated over and above the genome average ([Figures 2](#fig2){ref-type="fig"}A and [S2](#mmc1){ref-type="supplementary-material"}A). The importance of hypomethylation for enhancer and SE function in ESCs is well documented ([@bib10], [@bib38], [@bib48]) but has not been described in iPSC reprogramming. To validate the DMRs found from WGBS, an amplicon-based assay was designed. This assay allowed the methylation dynamics of selected regions to be interrogated at \>1,000-fold sequencing depth. The results closely matched those obtained from our low sequencing depth (3-fold) WGBS data, showing that such coverage nevertheless provided robust methylome information on individual loci ([Figure S2](#mmc1){ref-type="supplementary-material"}B). Unlike global demethylation, targeted demethylation occurs at the same regions and to a similar extent during female and male somatic cell reprogramming ([Figure 2](#fig2){ref-type="fig"}A).

Hierarchical clustering of RNA sequencing (RNA-seq) data of female cells during reprogramming showed that differentially expressed genes from MEFs to established iPSCs fell into five distinct expression clusters ([Figure S2](#mmc1){ref-type="supplementary-material"}C) similar to those previously described ([@bib26]). Notably, genes in cluster II (upregulated during reprogramming---including the pluripotency network genes) are enriched for hypomethylated DMRs in non-CGI promoters, ESC enhancers, and SEs ([Figure 2](#fig2){ref-type="fig"}B). Conversely, limb enhancer DMRs, which remain hypermethylated, are absent from this cluster. In contrast, genes in cluster V (downregulated during reprogramming) are exclusively enriched for DMRs at limb enhancers ([Figure 2](#fig2){ref-type="fig"}B). Similar results were seen for d6T^--^/S^+^ and ESCs ([Figure S2](#mmc1){ref-type="supplementary-material"}D), showing that upregulation of pluripotency genes precedes global demethylation and is influenced by targeted demethylation at ESC enhancers and super-enhancers. Instructive examples of changes in regulatory regions of individual genes are shown in [Figures 2](#fig2){ref-type="fig"}C, 2D, [S2](#mmc1){ref-type="supplementary-material"}E, and S2F. These results show that demethylation at specific regulatory regions is important for the upregulation of the pluripotency network genes. In established female and male iPSCs, depletion of methylation in ESC enhancers and non-CGI promoters was more pronounced in highly and very highly expressed genes ([Figure 3](#fig3){ref-type="fig"}A), in agreement with previous studies in ESCs ([@bib23], [@bib38]).

We developed a second analytical approach that utilizes methylation-matched random probes (MMRPs) to account for global methylation differences, which allows for clear visualization of methylation differences during iPSC reprogramming (relative to MEFs). This approach validates the targeted demethylation findings in both female and male cells ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B), and more importantly it allows for statistical significance to be calculated after grouping of the differences elicited by reprogramming, irrespective of the differences in the process or the genome coverage and sequencing depth of the data. Based on these analyses, we observed that DNA demethylation at ESC enhancers and super-enhancers is already evident in the intermediate-late stages of reprogramming but becomes yet more pronounced in d60 iPSCs ([Figures 3](#fig3){ref-type="fig"}B, 3C, [S3](#mmc1){ref-type="supplementary-material"}C, and S3D). Notably, we identified targeted demethylation at these same regulatory regions in pre-implantation embryos and during the serum to 2i transition ([Figure 3](#fig3){ref-type="fig"}D) while it was absent in unipotent PGCs ([@bib42]). These results reveal a conserved targeted demethylation signature during reprogramming to pluripotent cell identity in vitro and in vivo, which seems to be independent of the extent of global DNA demethylation.

AID Regulates UHRF1 and Global Demethylation during iPSC Reprogramming {#sec2.3}
----------------------------------------------------------------------

To understand the molecular regulation of global demethylation associated with female cell reprograming, we assessed the expression levels of genes implicated in DNA methylation and demethylation. As previously shown ([@bib5], [@bib29]), all *Dnmt* genes were significantly upregulated upon reprogramming ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Importantly, we also confirmed upregulation of DNMT1 and DNMT3b proteins ([Figures 4](#fig4){ref-type="fig"}A and [S4](#mmc1){ref-type="supplementary-material"}B). However, we observed one notable exception to this pattern UHRF1, responsible for the recruitment of DNMT1 to hemi-methylated DNA ([@bib3], [@bib33]). While its transcription was upregulated by reprogramming, we observed substantially reduced protein levels at the stages associated with global hypomethylation ([Figures 4](#fig4){ref-type="fig"}A and 4B), when compared to fully reprogrammed iPSCs.

AID has been previously implicated in iPSC reprogramming, but the timing, mechanisms, and extent of demethylation it may regulate are unknown ([@bib2], [@bib19]). It was therefore interesting to note that *Aid* expression peaked precisely in d29 iPSCs ([Figure 4](#fig4){ref-type="fig"}C) when DNA methylation levels are lowest. Moreover, global demethylation during reprogramming of female Aid knock-out (AidKO) MEFs was much less substantial and was delayed when compared to wild-type (WT) female cell reprogramming ([Figures 4](#fig4){ref-type="fig"}D, 4E, [S4](#mmc1){ref-type="supplementary-material"}C, and S4D). Typical reprograming-induced demethylation in female cells was partially rescued by re-expression of either the wild-type or a catalytically mutant isoform of AID, but not by expression of an empty vector ([Figure 4](#fig4){ref-type="fig"}F). These results show the importance of AID in regulating global DNA demethylation during reprogramming and that this regulation is independent of the deaminase activity of AID.

Given the marked abrogation of demethylation observed during reprograming of female AidKO MEFs, and the downregulation of UHRF1 protein associated with reprograming and global hypomethylation in WT cells, we compared UHRF1 protein levels during WT versus AidKO cell reprograming. Intriguingly, deficiency in AID prevented the downregulation of UHRF1 protein ([Figures 4](#fig4){ref-type="fig"}G and 4H). In addition, overexpression of AID (both WT and deaminase mutant) in AidKO reprogramming cells led to a significant decrease in UHRF1 protein levels ([Figures 4](#fig4){ref-type="fig"}I and 4J), consistent with a role for AID in regulating its abundance at a posttranscriptional level and reinforcing its importance in regulating global demethylation. We note in this respect the differential expression of genes involved in ubiquitination (which is known to regulate UHRF1 \[[@bib7]\]) between WT and AidKO d29 iPSCs ([Figure S4](#mmc1){ref-type="supplementary-material"}E), which included *Lonrf3*, *Mdm2*, *Usp48*, *Pramel7*, *Rnf32*, *Shprh*, and *Trim17* among others.

It is notable that despite the profound defect in the transient global demethylation associated with reprograming, we detected no differences in global methylation levels between WT and AidKO d60 iPSCs, presumably due to the de novo methylation wave that takes place at the later stages of reprograming. However, targeted demethylation at ESC-specific enhancers and super-enhancers was not affected by lack of AID ([Figure 4](#fig4){ref-type="fig"}K) consistent with the fact that in general activation of the pluripotency transcriptional program occurred normally in AidKO iPSCs ([Figure S4](#mmc1){ref-type="supplementary-material"}F). This is consistent with the mild effects of AID deficiency on obtaining iPSCs ([@bib14], [@bib34]). However we did identify more than 17,000 DMRs in AidKO iPSCs, most of which (72%) were hypermethylated ([Figure S4](#mmc1){ref-type="supplementary-material"}G). These hypermethylated DMRs occur throughout the genome and in all genomic features, consistent with a global effect of AID. Additionally, these cells appear to have impaired differentiation potential, as they are unable to upregulate several differentiation markers at the same levels as WT cells ([Figure S4](#mmc1){ref-type="supplementary-material"}H). These findings reconcile previous observations on AidKO iPSCs ([@bib19]), showing that global demethylation is mechanistically uncoupled from targeted demethylation and is necessary for the erasure of epigenetic memory.

Our data also showed significant upregulation of the ten-eleven Translocation (Tet) *Tet1* and *Tet2,* and *Tdg* genes in d29 iPSCs ([Figure S4](#mmc1){ref-type="supplementary-material"}I) that continue to be highly expressed in fully reprogrammed iPSCs. Hydroxymethylation levels were low in MEFs and d6T^+^/S^--^ cells, in contrast to d6T^--^/S^+^ cells that have hydroxymethylation levels similar to primed ESCs ([Figure S4](#mmc1){ref-type="supplementary-material"}J). This increase in 5-hydroxymethylcytosine (5hmC) correlates with the observed increase in expression of the *Tet* enzymes, consistent with their role in controlling MET ([@bib17]). Furthermore, the expression dynamics of *Tet1*, *2* and *Tdg* are consistent with a possible role in targeted but not in global demethylation.

Finally, based on the observation that female and male cells undergo global DNA demethylation to different extents, and when female cells are devoid of AID they show an extent of global demethylation similar to male WT cells, we investigated the status of X chromosome reactivation. We observed that AidKO female cells are able to reactivate the X chromosome, just like WT cells ([Figure S4](#mmc1){ref-type="supplementary-material"}K). Furthermore, to exclude that this could be a reprogramming system-specific effect, we reprogrammed fibroblasts from one male and four female human donors. Human cells also undergo global demethylation during reprogramming ([Figure S4](#mmc1){ref-type="supplementary-material"}L). However, this demethylation is not as profound as in female mouse cells, resembling more closely the male mouse global DNA methylation profile. Since human cells do not robustly reactivate the X chromosome during iPSC reprogramming ([@bib44]), we investigated whether this was the case in our reprogramming system. We observed that our human cells were not able to reactivate the X chromosome and *Xist* expression was maintained ([Figures S4](#mmc1){ref-type="supplementary-material"}M and S4N). Moreover, we observed that *Aid* is expressed at d11, when methylation levels are lower ([Figure S4](#mmc1){ref-type="supplementary-material"}O).

These results suggest that global DNA demethylation during reprogramming is mainly achieved by passive demethylation, similar to what has been reported in other reprogramming processes ([@bib32]). Furthermore, AID can influence the global methylation levels during reprograming by regulating the protein levels of UHRF1, and thus the efficiency of recruitment of the maintenance methylation machinery. Additionally, the extent of global DNA demethylation is not dependent on the reprogramming system or species but seems to be influenced by the capacity of cells to reactivate the X chromosome ([Figure 4](#fig4){ref-type="fig"}L).

Discussion {#sec3}
==========

The extent and role of DNA methylation remodeling during the reprogramming of somatic cells to pluripotency are poorly understood. Our detailed and comprehensive study reveals that iPSCs undergo transient global demethylation during reprogramming and that stable targeted demethylation occurs in parallel to the global one. Notably, we show that the targeted and global demethylation processes are mechanistically uncoupled and that upregulation of pluripotency genes precedes and is not dependent on the extent of global demethylation. Targeted demethylation establishes a unique epigenetic pluripotency signature, which is broadly conserved in other reprogramming processes. An important caveat is that there are gender-specific differences in the extent to which the genome demethylates globally. In female cells, where DNA demethylation is more pronounced, downregulation of UHRF1 protein, through an AID-dependent mechanism, facilitates global but not targeted demethylation ([Figure 4](#fig4){ref-type="fig"}L). Moreover, our results clearly show that cells lacking AID-mediated global demethylation have an impaired differentiation potential, showing that AID is important for epigenetic memory erasure but not for the establishment of pluripotent cell identity.

Global DNA demethylation occurs in early embryos, during PGC development and in naive ESCs in both mouse and human ([@bib45]) and has consequently been proposed to be a conserved and obligate feature of reprogramming ([@bib21], [@bib25]). Here, we show that mouse female and male cells undergo different levels of genome-wide demethylation during iPSC reprogramming. Our results, extrapolated from human cell reprogramming, point to a role for X chromosome reactivation in influencing these differences. This is consistent with mouse female ESCs having lower global methylation levels than male ones ([@bib51]) and with a recent report in PGC-like cell induction, where female cells undergo DNA methylation reprogramming similar to male cells, however, with more pronounced global changes ([@bib35]).

We reprogram MEFs to iPSCs in the presence of serum, which in ESCs results in high global methylation levels similar to those of somatic cells ([@bib12], [@bib15], [@bib22]). Hence despite high levels of de novo methyltransferases, controlled downregulation of UHRF1 protein seems critical for global demethylation. We have recently shown that UHRF1 is also regulated at the protein level when mouse ESCs are transitioned from serum to 2i ([@bib46]). This potentially provides a unifying theme for genome-wide demethylation mechanisms, which in mice and humans are characterized by disabling of the UHRF1/DNMT1 system, including by posttranscriptional regulation of *Uhrf1* ([@bib32], [@bib40]).

The role of AID in DNA demethylation and reprogramming in vivo and in vitro has been puzzling with the majority of studies demonstrating that it plays a role in demethylation ([@bib1], [@bib2], [@bib19], [@bib30], [@bib31]) but that it has mild impact on iPSC reprogramming ([@bib14], [@bib34]). Our results clearly show that AID plays a major role in global DNA demethylation, and unexpectedly this seems to be brought about by its negative regulation of UHRF1 protein levels, suggesting a novel role for AID in posttranslational regulation of UHRF1. Known mechanisms of UHRF1 regulation that can affect DNA methylation include ubiquitination among others ([@bib43]). We note in this respect that several ubiquitination and deubiquitination enzymes are differentially expressed in iPSCs with and without AID, and that AID itself interacts with a ubiquitin ligase ([@bib41]).

Targeted demethylation (over and above the global demethylation) occurs at ESC-specific enhancers and super-enhancers to a similar extent in female and male cells, and this is conserved in other reprogramming processes in which pluripotent cell identity is achieved. These regions share the characteristics of being CpG-poor and transcription factor (TF) binding-rich regions, characteristics that have been proposed to play a role in focal or targeted demethylation ([@bib36], [@bib38]). TET proteins have also been implicated in reprogramming ([@bib25]), as well as in targeted enhancer ([@bib28]) and super-enhancer ([@bib10]) demethylation in ESCs. However, Tet enzymes are needed specifically for activation of microRNAs essential for iPSC derivation, and it is possible to obtain fully reprogrammed iPSCs from *Tet1-3* triple-knockout MEFs after ectopic expression of miR200c ([@bib17]). Nevertheless, the dynamics of *Tet* enzyme expression and of the hydroxymethylation levels that we observe suggest they may play a role in the fine-tuning of targeted demethylation. Indeed, a model that seeks to explain DNA methylation dynamics at enhancers during differentiation has been proposed ([@bib16]). This model suggests that at TF binding-rich enhancers, binding of TFs excludes DNMT1 activity, leading to their demethylation, whereas in TF binding-poor enhancers, TET2 protein is crucial in fine-tuning enhancer methylation in an oxidation-dependent manner. We suggest that a similar mechanism could be responsible for the targeted remodeling of these regions during reprogramming.

In contrast, AID does not have a role in targeted demethylation of pluripotency regulatory regions, but its absence results in widespread hypermethylated epialleles in iPSCs. This explains why AID-deficient iPSCs can be obtained, but cells with residual and persistent epigenetic memory may well behave aberrantly and unpredictably in potential future therapeutic settings, given their altered differentiation potential. It will be interesting to investigate further the differences in developmental potential between female and male iPSCs, which could impact on their use in basic and translational research. Hence, in a process where cells have to switch off a somatic expression program and upregulate a pluripotency network, global DNA demethylation seems to be important for the removal of epigenetic memory, while targeted demethylation at regulatory regions, and, in particular, at ESC super-enhancers, is crucial for the establishment of the pluripotent identity. Understanding and manipulating the two demethylation processes may result in improvements in the safety and the efficiency of obtaining robust, high quality iPSCs, prerequisites for therapeutic applications in regenerative medicine.

Experimental Procedures {#sec4}
=======================

Reprogramming of MEFs to iPSCs {#sec4.1}
------------------------------

For each transfection, 0.8 × 10^6^ MEFs were nucleofected using Amaxa Nucleofection Technology (Lonza AG; program A-023), according to the manufacturer's instructions, with 1 μg of each plasmid. Plasmids for reprogramming pB-TRE-OCKS, pBASE, and pB-CAG-rtTA were obtained from the Wellcome Trust Sanger Institute's plasmid repository. Reprogramming was performed in ESC medium (DMEM, 15% fetal bovine serum, 1% anti-anti, 1% MEM non-essential amino acids, 50 μM b-mercaptoethanol, and 10^3^ U leukemia inhibitory factor \[LIF\]) in the presence or absence of doxycycline, in a 5% O~2~ incubator. The medium was refreshed every other day. Colonies were picked on day 6 of reprogramming and expanded for at least 54 days. Cells were collected at different time points during reprogramming: mouse embryonic fibroblasts (MEFs), d6 fluorescence-activated cell sorted (FACS) refractory cells positive for Thy1 and negative for SSEA1 surface markers (d6T^+^/S^--^), and early reprogramming intermediates negative for Thy1 and positive for SSEA1 (d6T^--^/S^+^) as well as the reprogramming of individual colonies at intermediate-late stages of reprogramming (d21 iPSC and d29 iPSC) and established iPSCs (d60 iPSC).

All animal work carried out in this study is covered by a project license under the Animal (Scientific Procedures) Act 1986, and further regulated by the Babraham Institute Animal Welfare, Experimentation, and Ethics Committee.
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![Global DNA Demethylation Dynamics during iPSC Reprogramming\
(A) Scheme of the reprogramming system. d6T^+^/S^--^ and d6T^--^/S^+^: Thy1 (T) and SSEA1 (S) FACS cells at day 6 of reprogramming. For detailed description, refer to [Experimental Procedures](#sec4){ref-type="sec"}.\
(B) Global 5mC levels measured by LC-MS. Results are expressed as percentage of total cytosines and data are represented as mean ± SEM p values shown are the result of an ANOVA with Dunnett's correction.\
(C--E) CpG methylation levels, as assessed by BS-seq, during reprogramming of (C) female, (D) male cells, and (E) pre-implantation embryo (oocyte, 2- and 4-cell embryos, ICM, and epiblast). (C--E) Plot displays the median (bar), inter-quartile range (box), and maximum and minimum (whiskers).\
See also [Figure S1](#mmc1){ref-type="supplementary-material"}.](gr1){#fig1}

![Correlation of DNA Methylation at Different Regulatory Regions and Gene Expression\
(A) Scatterplot of DNA methylation levels of individual probes genome-wide, showing whole genome and different genomic features of MEFs and d60 iPSCs. Dots represent individual 50 CpG probes---significant differentially methylated regions (DMRs) are represented in green (female cell reprogramming) or blue (male cell reprogramming). Background model depicted as a black line.\
(B) Percentage of DMRs at regulatory regions that overlap with specific gene clusters, compared to random sets with the same number of genes (in gray).\
(C) Expression profiles (reads per kilobase pre million mapped reads \[RPKM\]) for *Tdgf1*, *Gdf3*, *Dppa3*, and *Slc2a3*.\
(D) Example of BS-seq profile for *Tdgf1*, *Gdf3*, *Dppa3*, and *Slc2a3* at promoter, enhancer, and SE regions. Methylation levels of individual probes, between 0% and 100% are shown. Shadowed areas highlight promoter (P), enhancer (E), or super-enhancer (SE) regions.\
See also [Figure S2](#mmc1){ref-type="supplementary-material"}.](gr2){#fig2}

![DNA Demethylation Dynamics at Specific Genomic Features and in Different Reprogramming Processes\
(A) CpG methylation levels for promoter and enhancer regions of genes showing different expression levels in female d60 iPSCs.\
(B and C) Density plots of methylation differences from MEFs to each time point in reprogramming of (B) female and (C) male cells and ESCs, at specific features shown by opaque plots, overlaid by MMRP transparent gray density plot.\
(D) Density plots of methylation differences at specific features, from oocyte to each time point in pre-implantation embryo, epiblast to PGCs and serum to 2i ESCs, shown by opaque plots; overlaid by MMRP transparent gray density plot. (B--D) Analyses were performed for ESC enhancers and SE Δ denotes a minimum 5% difference between data and MMRP profile. p values shown are the result of a pairwise t test with a Benjamini-Hochberg correction.\
See also [Figure S3](#mmc1){ref-type="supplementary-material"}.](gr3){#fig3}

![Mechanisms of DNA Demethylation\
(A) WB showing levels of DNMT1 and UHRF1 in WT iPSCs at d29 and d60. β-actin was used as a loading control.\
(B) Quantitation of DNMT1 and UHRF1 WB bands, relative to ESCs levels.\
(C) Expression profile (RPKM) for *Aid*. p values shown are the result of two-tailed t tests from MEFs to d29 iPSCs.\
(D) Global 5mC levels, measured by LC-MS. Results are expressed as percentage of total cytosine. Data are represented as mean ± SEM. Shown are results for reprogramming of WT and AidKO MEFs.\
(E) Global CpG methylation levels, as assessed by BS-seq, for every time point during AidKO MEF reprogramming. Plot displays the median (bar), inter-quartile range (box), and maximum and minimum (whiskers).\
(F) Global 5mC levels, measured by LC-MS. Results are expressed as percentage of total cytosine. Data are represented as mean ± SEM. Shown are results for AidKO MEFs reprogrammed with the OSKM plus an empty vector (EV), a vector containing AID WT cDNA (AIDWt), or a vector containing AID catalytic mutant cDNA (AIDCatMutt).\
(G) WB showing levels of DNMT1 and UHRF1 in AidKO iPSCs at d29 and d60. β-actin was used as a loading control.\
(H) Quantitation of DNMT1 and UHRF1 WB bands, relative to ESCs levels.\
(I) WB showing levels of UHRF1 in WT and AidKO iPSCs d29 and clones rescued with EV, AIDWtor AIDCatMutt. β-actin was used as a loading control.\
(J) Quantitation of UHRF1 WB bands (arbitrary units \[a.u.\]).\
(K) Density plots of methylation differences at ESC enhancer and SE from AidKO MEFs to iPSCs, shown by opaque plots. Overlaid by MMRP transparent gray density plot. Δ denotes a minimum 5% difference between data and MMRP profile p values shown are the result of a pairwise t test with a Benjamini-Hochberg correction.\
(L) Proposed model to explain role of AID in DNA methylation dynamics during iPSC reprogramming.\
See also [Figure S4](#mmc1){ref-type="supplementary-material"}.](gr4){#fig4}
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